Terumo Corp
TSE:4543
Operating Margin
Terumo Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Terumo Corp
TSE:4543
|
4T JPY |
15%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.4B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
192.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
154.6B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.9B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.4B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.1B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.1B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.5B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
281.2B CNY |
34%
|
Terumo Corp
Glance View
In the bustling corridors of Tokyo, Terumo Corporation stands as a testament to Japan's prowess in medical innovation, deeply rooted in a legacy that began over 90 years ago. Born from the vision of a group of scientists aiming to improve Japan’s healthcare system, Terumo embarked on its journey by developing high-quality thermometers. This modest start set the stage for what would become a global leader in medical technology. Anchored by its commitment to enhancing patient care and healthcare practices, Terumo carved out a significant niche by focusing on cardiovascular systems, blood transfusion, and cell therapy technologies. As the company grew, it systematically increased its range, moving into areas such as vascular intervention and diabetes care, aligning with evolving medical needs around the globe. Today, Terumo generates its revenue through a multi-faceted business model that thrives on innovation and globalization. It operates through several segments: Cardiovascular, General Hospital, and Blood Management. The Cardiovascular division, a major revenue driver, offers products ranging from stents to heart-lung machines used in cardiac surgeries. Meanwhile, the General Hospital unit provides hospital equipment like infusion pumps and syringe systems, while the Blood Management segment is renowned for its blood and cell processing systems. Terumo’s ability to innovate within these domains enhances its competitive edge by delivering cutting-edge medical solutions. By balancing its expansive product portfolio with a strong focus on research and development, the company not only sustains but frequently advances the standards of modern healthcare, ensuring its continued success in diverse international markets.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Terumo Corp's most recent financial statements, the company has Operating Margin of 15.2%.
You don't have any saved screeners yet